Federal • US Congress
H.R. 9418: Access to Innovative Treatments Act of 2026
Rep. Nanette Barragán (D-CA)Referred
H.R. 9418 status: Referred.
1
What this bill does
Overall score
Score70/100 civic fit
RiskLow risk
ImpactHigh impact
Bill summary
No official summary is available for this bill yet.
Key analysis
Constitutionality80%
Bipartisan60%
Public opinion70%
2
Impact analysis
Environment
Mixed / Neutral
50%
Benefits
- No direct environmental benefit identified
Risks
- No direct environmental risk identified
Economy
Positive Outlook
75%
Benefits
- Expands access to innovative drugs for Medicare beneficiaries.
- May stimulate pharmaceutical innovation by providing clearer coverage pathways.
Risks
- Potential for increased Medicare spending due to broader drug coverage.
Society
Positive Outlook
75%
Benefits
- Improves patient access to potentially life-saving or life-improving treatments.
- Establishes a more transparent and timely review process for drug coverage decisions.
Risks
- May create disparities if review processes are not uniformly applied.
3
How trustworthy & consequential it is
Confidence
highhigh
Information is complete and verified.
Analysis status
Full bill text (Congress.gov)
Source used for this bill's analysis.
Warning
The actual impact on Medicare spending is not quantified in the bill text.
Limitation
The review process is subject to limitations on successive reviews within a two-year period.
4
Where it stands
Introduced
Complete2
Committee
CurrentReferred
3
Floor
Upcoming4
Enacted
Upcoming5
How it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
6
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.